EYEN - Eyenovia Inc Stock Price, Fair Value and News

$0.090.00 (0.00%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

EYEN Price Action

Last 7 days

12.5%

Last 90 days

-82%

Trailing 12 Months

-94.6%

EYEN RSI Chart

EYEN Valuation

Market Cap

7.8M

Price/Earnings (Trailing)

-0.21

Price/Sales (Trailing)

1.8K

Price/Free Cashflow

-0.25

EYEN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

EYEN Fundamentals

EYEN Revenue

Revenue (TTM)

3.8K

Rev. Growth (Yr)

-99.98%

Rev. Growth (Qtr)

-92.82%

EYEN Earnings

Earnings (TTM)

-37.8M

Earnings Growth (Yr)

-7.48%

Earnings Growth (Qtr)

28.64%

EYEN Profitability

Operating Margin

-16225.51%

Return on Equity

-1.0K%

Return on Assets

-165.95%

Free Cashflow Yield

-393.42%

EYEN Investor Care

Shares Dilution (1Y)

95.91%

Diluted EPS (TTM)

-0.71

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	7.0M	3.8K
2021	5.0M	8.0M	11.0M	14.0M
2020	0	0	0	2.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About Eyenovia Inc

Eyenovia, Inc., a pre-commercial ophthalmic company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. It focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi in rest of Asia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.

CEO	Mr. Michael M. Rowe
WEBSITE	eyenovia.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	41

Eyenovia Inc Frequently Asked Questions

What is the ticker symbol for Eyenovia Inc? What does EYEN stand for in stocks?

EYEN is the stock ticker symbol of Eyenovia Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Eyenovia Inc (EYEN)?

As of Fri Dec 20 2024, market cap of Eyenovia Inc is 7.78 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EYEN stock?

You can check EYEN's fair value in chart for subscribers.

Is Eyenovia Inc a good stock to buy?

The fair value guage provides a quick view whether EYEN is over valued or under valued. Whether Eyenovia Inc is cheap or expensive depends on the assumptions which impact Eyenovia Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EYEN.

What is Eyenovia Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, EYEN's PE ratio (Price to Earnings) is -0.21 and Price to Sales (PS) ratio is 1.83 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EYEN PE ratio will change depending on the future growth rate expectations of investors.